FDA OKs Novo Nordisk's Fiasp for infusion pumps - MassDevice
Fiasp® Onset of Appearance | Fiasp® (insulin aspart injection) 100 U/mL
NovoLog® Insulin Pen Options | NovoLog® (insulin aspart injection) 100 U/mL
The Latest and Greatest in Insulin Pumps and Sensor Technology - Taking Control Of Your Diabetes
Diabetes and Insulin Pens - Guide to Insulin Pens
Insulin Pump Therapy for Type 2 Diabetes | Medtronic Diabetes
Evidence for Type 2s to go on insulin pumps
Medtronic and Novo Nordisk announce major diabetes collaboration - Diabetes
Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial - The Lancet Diabetes & Endocrinology
Novo Nordisk to launch connected insulin pens - PMLiVE
Insulin pumps in general practice - Australian Prescriber
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial - The Lancet
Insulin Pump Therapy for Type 2 Diabetes | Medtronic Diabetes
Novo Nordisk's new insulin pens will integrate with Abbott's Freestyle Libre system | MobiHealthNews
Novo's New Faster-Acting Insulin FIASP | DiabetesMine
Insulin pumps tied to over 2,000 injuries recalled | Pharmafile
Insulin 100 years
Health Canada approves fast-acting mealtime insulin, Fiasp®, for children with diabetes
EU Approves Novo Nordisk's Pre-filled Insulin Cartridge for the New Accu-Chek Insight Insulin Pump
Smart Insulin or Glucose Responsive Insulin Market Size | Growth, 2027
Global Insulin Pens, Syringes, Pumps And Injectors Market Report
Diabetes Devices Market: Increase in Adoption of Insulin Pump among Type 1 Diabetes Patients Boost Market Growth | Medgadget
Insulin Pump Therapy for Type 2 Diabetes | Medtronic Diabetes
Surge in FDA Approvals for Diabetes Devices and Product Advances
